Ovarian
The trials listed below are accepting new patients. Interested patients can Email the coordinator by clicking on envelope icon. Please include a phone number and best times to call.
Treatment Phase |
Protocol Title |
ClinicalTrial.Gov link |
Penn Research Coordinator |
Am I Eligible? |
|---|---|---|---|---|
|
Newly diagnosed stage 2-4 |
NRG-GY019: Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian or Primary Peritoneal Cancer |
|
Eligibility Criteria | |
| Recurrent |
STRO+bev: A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha (FolRα) Antibody DrugConjugate (ADC), in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) |
NCT05200364 | Destany Fields |
Enrollment on Hold |
| Recurrent | ATRN: A Phase 1/2a, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral ATRN-119 in Patients with Advanced Solid Tumors | NCT04905914 | Andrea Standish, RN | Eligibility Criteria |
| Recurrent | GOG 3066: A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT04814108 | Kristina Powell | Eligibility Criteria |
| Recurrent | STAR-101: A Phase 1 Study of SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR, in Subjects with Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma | NCT05568680 | Andrea Standish, RN | Eligibility Criteria |
| Recurrent | NP-G2-044-P2-01: NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies | NCT05023486 | Shavon Rochester | |
| Recurrent | NRG-GY031: A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN003694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer | NCT05950464 | Christine Pae | Eligibility Criteria |
| Recurrent | Phase 1/2 Study of REGN5668 (MUC16 X CD28, A Costimulatory Bispecific) Administered in Combination with Cemiplimab or REGN4018 (MUC16 X CD3) | NCT04590326 | Katie Hayes, RN | Eligibility Criteria |
| Maintenance | UPROAR: A phase II evaluation of maintenance therapy combination Mirvetuximab Soravtansine and Olaparib in Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer | NCT05887609 | Kristina Powell | Eligibility Criteria |
| Surgery | CC008: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk] | NCT04251052 | Kristina Powell | Eligibility Criteria |
| Surgery | WISP II: Tubectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention | NCT04294927 | Christine Pae | Eligibility Criteria |